Results 51 to 60 of about 13,248 (184)

Adverse Event Signals Associated with Beta-Lactamase Inhibitors: Disproportionality Analysis of USFDA Adverse Event Reporting System

Journal of Xenobiotics
Background: Beta-lactamase inhibitors (BLIs) are widely used with beta-lactam antibiotics to combat resistant infections, yet their safety profiles, especially for newer agents, remain underexplored.
Kannan Sridharan, Gowri Sivaramakrishnan
doaj   +1 more source

Struggle To Survive: the Choir of Target Alteration, Hydrolyzing Enzyme, and Plasmid Expression as a Novel Aztreonam-Avibactam Resistance Mechanism

mSystems, 2020
Aztreonam-avibactam is a promising antimicrobial combination against multidrug-resistant organisms, such as carbapenemase-producing Enterobacterales. Resistance to aztreonam-avibactam has been found, but the resistance mechanism remains poorly studied ...
Ke Ma, Yu Feng, Alan McNally, Zhiyong Zong   +3 more
doaj   +1 more source

Bloodstream infection caused by KPC-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam: epidemiology and genomic characterization [PDF]

, 2020
Objectives: The aim of this study was to evaluate the incidence of ceftazidime/avibactam resistance among Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae (KPC-Kp) strains isolated from patients with bloodstream infection.
Ambretti S., Viale P. L., Gaibani P., Campoli C., Re M. C.   +4 more
core   +1 more source

Clonal lineage and biofilm growth shape cefiderocol activity in Acinetobacter baumannii from oncology patients

Frontiers in Cellular and Infection Microbiology
IntroductionAcinetobacter baumannii is a leading cause of healthcare-associated infections in immunocompromised patients and frequently exhibits multidrug resistance.
Ilaria Cavallo, Francesca Sivori, Mauro Truglio, Massimo Francalancia, Elva Abril, Giorgia Fabrizio, Sara Petrolo, Francesca Maione, Grazia Prignano, Arianna Mastrofrancesco, Fulvia Pimpinelli, Enea Gino Di Domenico   +11 more
doaj   +1 more source

Combination of Oral Doxycycline and Rifampin for Pan‐Drug Resistant Klebsiella pneumoniae Infection: A Case Report

Clinical Case Reports, Volume 14, Issue 8, August 2026.
ABSTRACT Pan‐drug resistant Klebsiella pneumoniae is a major therapeutic challenge, particularly when standard last‐line agents are unavailable or contraindicated. We report a 45‐year‐old man with multifocal osteomyelitis and persistent purulent wound discharge despite broad‐spectrum antibiotics, repeated debridement, and two sequential amputations ...
Ali Akbar Heydari, Sepideh Elyasi, Farshad Abedi   +2 more
wiley   +1 more source

First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate [PDF]

, 2015
Ceftazidime-avibactam is the first antimicrobial approved by the U.S. FDA for the treatment of carbapenem-resistant Enterobacteriaceae. Avibactam, a non-β-lactam β-lactamase inhibitor, inactivates class A serine carbapenemases, including Klebsiella ...
Humphries, Romney M, Yang, Shangxin, Hemarajata, Peera, Gregson, Aric, Hindler, Janet A, Ward, Kevin W, Miller, Shelley A   +6 more
core   +1 more source

Activity of aztreonam/avibactam and ceftazidime/avibactam against Enterobacterales with carbapenemase-independent carbapenem resistance [PDF]

Enterobacterales with carbapenemase-independent resistance to carbapenems are sometimes selected during therapy and, on rare occasions, cause outbreaks. Most have extended-spectrum or AmpC β-lactamases, together with changes to permeability or penicillin-
Vickers, Anna, Livermore, David M., Woodford, Neil, Mushtaq, Shazad   +3 more
core   +1 more source

The Rapid CarbaLux Combination Test to Uncover Bacterial Resistance and Heteroresistance Prior to Antibiotic Treatment

Diagnostics
Background/Objectives: In this proof-of-concept study, the objective was to evaluate the phenotypic CarbaLux combination rapid test in terms of guiding the therapy of infections caused by multidrug-resistant Gram-negative bacteria with carbapenemase ...
Hans Rudolf Pfaendler, Hans-Ulrich Schmidt   +1 more
doaj   +1 more source

Ceftazidime-Avibactam Therapy Versus Ceftazidime-Avibactam-Based Combination Therapy in Patients With Carbapenem-Resistant Gram-Negative Pathogens: A Meta-Analysis

Frontiers in Pharmacology, 2021
Objective: To systematically review and compare the efficacy and posttreatment resistance of ceftazidime-avibactam therapy and ceftazidime-avibactam-based combination therapy in patients with Gram-negative pathogens.Methods: PubMed, Embase, Web of ...
Dan Li, Dan Li, Dan Li, Fan Fei, Hua Yu, Xiangning Huang, Shanshan Long, Hao Zhou, Jie Zhang   +8 more
doaj   +1 more source

Longitudinal Molecular Epidemiology and Genomic Surveillance of Carbapenem‐Resistant Klebsiella pneumoniae in the Gut of Healthy Individuals in China

MedComm, Volume 7, Issue 8, August 2026.
Using 16,040 stool samples from healthy individuals across 30 Chinese provinces (2016–2024), we performed longitudinal genomic surveillance of carbapenem‑resistant Klebsiella pneumoniae (CRKP) colonizing the gut. We reveal rising community CRKP prevalence, especially in southern China, a shift from blaKPC‐2 to plasmid‑borne blaNDM‐5 on IncHI2/IncHI2A ...
Zelin Yan, Yan Li, Yi Sun, Qiaoling Sun, Congcong Liu, Yanyan Zhang, Yuchen Wu, Hongwei Zhou, Shangshang Qin, Gongxiang Chen, Ruichao Li, Rong Zhang   +11 more
wiley   +1 more source